Abstract: The disclosure provides compounds, and compositions comprising such compounds, that can be used to treat CXCR5-expressing cancers, especially angioimmunoblastic T cell lymphoma (AICL) and/or cutaneous T cell lymphoma (CTCL).

Abstract: Methods and compositions are provided for the treatment of an autoimmune disease. The methods include administering immunoregulatory T cells (Tregs) to patients. The therapeutic Tregs can express the CD25, CD4, and/or ICOS antigens. The therapeutic T cells can be CD25+ ICOS+, CD4+ICOS+, and/or CD25+ CD4+ ICOS+, and they can be provided by a donor.

Abstract: The present invention relates to methods for treating a subject predisposed to an autoimmune disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the autoimmune disease. The present invention alsorelates to methods for treating a subject predisposed to an atopic disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manitfesation of a symptom associated with the atopic disease. The present invention further relates to methods for treating a transplant donor and/or a transplant recipient, or an implant recipient with extracorporeal photopheresis or an effective amount of apoptotic cells prior to the transplant or implantation procedure.

Abstract: The present invention is based, in part, on the discovery that mutating IL-7 in the region of the carboxy terminus, can result in modification of receptor ligand interactions between IL-7 and IL-7 receptor (IL-7R). Compounds that modify such interaction, which are also within the scope of the invention, can be used to treat T-cell-mediated disorders.